SCHEMBL10196809

SCHEMBL10196809

CCOC(=O)C(C)(C)CC(=O)c1ccc(OC2CCN(C)CC2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
TDO2 P48775 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
SCN1A P35498 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN3A Q9NY46 1/20 0.39
MAPK7 Q13164 1/20 0.38
NAMPT P43490 3/20 0.37
LIPE Q05469 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3622118 0.87 GPR119 (0.57) GPR119HRH3
SCHEMBL796507 0.78 HRH3 (0.49) HRH3SCN1ASCN2ASCN3AMAPT
SCHEMBL10196808 0.77 TDO2 (0.48) GPR119HDAC3HDAC4HDAC1HDAC7
SCHEMBL3346693 0.73 GPR119 (0.62) GPR119HRH3MAPT
SCHEMBL795847 0.71 MAPT (0.49) TDO2HRH3SCN1ASCN2ASCN3A
SCHEMBL13432215 0.70 TDO2 (0.50) TDO2HRH3SCN1ASCN2ASCN3A
SCHEMBL20069064 0.69 TDO2 (0.47) TDO2HRH3NAMPTLIPEDYRK1A
SCHEMBL601775 0.69 DGAT1 (0.43) GPR119HRH3MAPT
SCHEMBL601774 0.69 DGAT1 (0.43) GPR119HRH3MAPT
SCHEMBL31003114 0.69 MAPT (0.46) GPR119HRH3NAMPTMAPTOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 US disclosed
US-8586588-B2 Aryl pyridazinone derivatives and their use as H3 receptor ligands CEPHALON, INC. (US) 2013-11-19 US disclosed
US-8247414-B2 Pyridizinone derivatives and the use thereof as H3 inhibitors CEPHALON, INC. (US) 2012-08-21 US disclosed
US-8207168-B2 Pyridazinone derivatives CEPHALON, INC. (US) 2012-06-26 US disclosed
US-20110288075-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2011-11-24 US disclosed
US-20100280007-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-11-04 US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 US disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027041-A1 Pyridizinone derivatives H1-5, H1-3, H1-4 GPR119 1540/4885HDAC3 24/4885HDAC4 39/4885
US-20100280007-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 GPR119 660/4885HDAC3 484/4885HDAC4 211/4885
US-20110288075-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 GPR119 681/4885HDAC3 411/4885HDAC4 177/4885
US-20140142088-A1 PYRIDAZINONE DERIVATIVES HRH3, HNMT, HRH4 GPR119 611/4885HDAC3 368/4885HDAC4 175/4885
US-20100273779-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 GPR119 660/4885HDAC3 484/4885HDAC4 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.